Tacrolimus (Page 11 of 17)

8.8 Race or Ethnicity

African-American patients may need to be titrated to higher dosages to attain comparable trough concentrations compared to Caucasian patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)] .

African-American and Hispanic patients are at increased risk for new onset diabetes after transplant. Monitor blood glucose concentrations and treat appropriately [see Warnings and Precautions (5.4)] .

10 OVERDOSAGE

Limited overdosage experience is available. Acute overdosages of up to 30 times the intended dose have been reported. Almost all cases have been asymptomatic and all patients recovered with no sequelae. Acute overdosage was sometimes followed by adverse reactions consistent with those listed in Adverse Reactions (6)(including tremors, abnormal renal function, hypertension, and peripheral edema); in one case of acute overdosage, transient urticaria and lethargy were observed. Based on the poor aqueous solubility and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus is not dialyzable to any significant extent; there is no experience with charcoal hemoperfusion. The oral use of activated charcoal has been reported in treating acute overdoses, but experience has not been sufficient to warrant recommending its use. General supportive measures and treatment of specific symptoms should be followed in all cases of overdosage.

In acute oral and IV toxicity studies, mortalities were seen at or above the following doses: in adult rats, 52 times the recommended human oral dose; in immature rats, 16 times the recommended oral dose; and in adult rats, 16 times the recommended human IV dose (all based on body surface area corrections).

11 DESCRIPTION

Tacrolimus, previously known as FK506, is the active ingredient in tacrolimus capsules. Tacrolimus is a calcineurin-inhibitor immunosuppressant produced by Streptomyces tsukubaensis. Chemically, tacrolimus is designated as (-)-(3 S ,4 R ,5 S ,8 R ,9 E ,12 S ,14 S ,15 R ,16 S ,18 R ,19 R ,26a S)-8-Allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[( E)-2-[(1 R ,3 R ,4 R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-14,16-dimethyoxy-4,10,12,18-tetramethyl-15,19-epoxy-3 H -pyrido[2,1- c ][1,4]oxaazacyclotricosine-1,7,20,21(4 H ,23 H)-tetrone)monohydrate.

The chemical structure of tacrolimus is:

Tacrolimus Structural Formula

Tacrolimus has a molecular formula of C 44 H 69 NO 12 •H 2 O and a formula weight of 822.03. Tacrolimus, USP appears as a white to off-white powder. It is insoluble in water, very soluble in ethanol, and soluble in methanol and chloroform.

Tacrolimus capsules, USP are available for oral administration as capsules containing the equivalent of 0.5 mg, 1 mg or 5 mg of anhydrous tacrolimus. Inactive ingredients include anhydrous lactose, black iron oxide, colloidal silicon dioxide, croscarmellose sodium, gelatin, hypromellose, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.

The 0.5 mg capsules also contain D&C Red No. 28, D&C Yellow No. 10 and FD&C Red No. 40, the 1 mg capsules also contain FD&C Blue No. 1 and FD&C Red No. 3 and the 5 mg capsules also contain D&C Red No. 33, D&C Red No. 28 and D&C Yellow No. 10.

In addition, the black imprinting ink contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.

Meets USP Dissolution Test 5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB).

Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor-alpha, and granulocyte macrophage colony-stimulating factor. Tacrolimus also inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis and production of transforming growth factor beta that can lead to immunosuppressive activity. The net result is the inhibition of T-lymphocyte activation and proliferation, as well as T-helper-cell-dependent B-cell response (i.e., immunosuppression).

12.3 Pharmacokinetics

Tacrolimus activity is primarily due to the parent drug. The pharmacokinetic parameters (mean ± S.D.) of tacrolimus have been determined following intravenous (IV) and/or oral (PO) administration in healthy volunteers, and in kidney transplant, liver transplant, and heart transplant patients (Table 17).

Table 17. Pharmacokinetics Parameters (mean ± S.D.) of Tacrolimus in Healthy Volunteers and Patients
*
not applicable
AUC 0-inf
not available
§
AUC 0-t
Determined after the first dose
#
Median [range]
Þ
AUC 0-12

Population

N

Route (Dose)

Parameters

C max (ng/mL)

T max

(hr)

AUC (ng•hr/mL)

t 1/2 (hr)

CL (L/hr/kg)

V (L/kg)

Healthy Volunteers

8

IV (0.025 mg/kg/4hr)

*

*

652 ± 156

34.2 ± 7.7

0.040 ± 0.009

1.91 ± 0.31

30

PO (5 mg) (granules)

35.6 ± 10.9

1.3 ± 0.5

320 ± 164

32.1 ± 5.9

PO (5 mg) (capsules)

28.8 ± 8.9

1.5 ± 0.7

266 ± 95

32.3 ± 8.8

IV (0.02 mg/kg/12 hr)

*

*

294 ± 262

18.8 ± 16.7

0.083 ± 0.050

1.41 ± 0.66

Kidney Transplant Patients

26

PO (0.2 mg/kg/day)

19.2 ± 10.3

3.0

203 ± 42

PO (0.3 mg/kg/day)

24.2 ± 15.8

1.5

288 ± 93

Liver Transplant Patients

17

IV (0.05 mg/kg/12 hr)

*

*

3300 ± 2130

11.7 ± 3.9

0.053 ± 0.017

0.85 ± 0.30

PO (0.3 mg/kg/day)

68.5 ± 30.0

2.3 ± 1.5

519 ± 179

11

IV (0.01 mg/kg/day as a continuous infusion)

*

*

954 § ± 334

23.6 ± 9.22

0.051 ± 0.015

Heart Transplant Patients

11

PO (0.075 g/kg/day)

14.7 ± 7.79

2.1 [0.5-6.0] #

82.7 Þ ± 63.2

*

14

PO (0.15 mg/kg/day)

24.5 ± 13.7

1.5 [0.4-4.0] #

142 Þ ± 116

*

Due to intersubject variability in tacrolimus pharmacokinetics, individualization of the dosing regimen is necessary for optimal therapy [see Dosage and Administration (2.6)] . Pharmacokinetic data indicate that whole blood concentrations rather than plasma concentrations serve as the more appropriate sampling compartment to describe tacrolimus pharmacokinetics.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.